Importantly, our data demonstrate that silencing TRAF3IP2 significantly reduced the expression of pro-angiogenic markers, including CD31, CD34, and VEGF, in induced intracranial GBM tumors (Figure 2). This evidence concerns the gene PECAM1 and glioblastoma.